CellSource Co., Ltd. (JP:4880)
:4880
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥360.00 - ¥798.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥7.70B
Enterprise Value¥3.10B
Total Cash (Recent Filing)¥4.71B
Total Debt (Recent Filing)¥56.72M
Price to Earnings (P/E)59.4
Beta0.79
Next Earnings
Jun 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)1.70
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.83
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.1
Revenue Forecast (FY)¥3.45B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetCellSource's minimal leverage and high equity base give durable financial flexibility to fund R&D, manufacturing and partnerships without heavy reliance on external debt. This conservatism improves resilience through biotech revenue cycles and supports strategic investments over the medium term.
Positive Cash GenerationConsistent positive operating and free cash flow provides internal funding for operations, capex and clinical collaborations, reducing refinancing needs. Despite volatility and a 2024–25 decline, ongoing cash generation supports sustainable operations and execution of growth initiatives.
Recurring Contract-processing GrowthRising contract-processing volumes in hybrid orthopedics and OB&GYN reflect deeper penetration of recurring service revenue and successful business-support measures. Diversification away from self-funded and aesthetic demand can stabilize revenue mix and underpin durable service margins.
Bears Say
Sharp Profitability DeteriorationProfitability and returns have eroded materially, with net margin collapsing to near break-even. Sustained weak margins constrain reinvestment, limit ability to fund growth organically, and create pressure to restructure costs or seek external capital to restore returns.
Full-year Sales Decline And Forecasted LossAn unchanged outlook calling for lower full-year sales and a net loss signals structural demand or pricing weaknesses. Expected annual earnings deterioration increases uncertainty for long-term planning, may force conservative capital allocation, and undermines sustainable profitability.
Listing Shift From Prime To Standard MarketThe move to the Standard Market is a structural governance/listing change reflecting smaller tradable float. Over time this can reduce institutional visibility and liquidity, potentially raising cost of capital and constraining large equity raises or strategic transactions.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥360.00 and its highest was ¥798.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥7.70B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Jun 15, 2026 which is in 78 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Mar 17, 2026. The company reported ¥1.7 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.7.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.7 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.571%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―